A decision-theoretic framework for the application of cost-effectiveness analysis in regulatory processes

PharmacoEconomics

Volumn 27, Issue 8, 2009, Pages 645-655

  Baio, Gianluca ^a,b   Russo, Pierluigi ^c  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ITALIAN MEDICINES AGENCY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTON PUMP INHIBITOR;

BAYES THEOREM; COMPARATIVE STUDY; CONCEPTUAL FRAMEWORK; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; ECONOMICS; MARKET; MEDICAL INFORMATION; PRIORITY JOURNAL; REVIEW; UNCERTAINTY;

BAYES THEOREM; COST-BENEFIT ANALYSIS; DECISION MAKING; DRUG COSTS; HUMANS; LEGISLATION, DRUG; MODELS, ECONOMIC; PHARMACEUTICAL PREPARATIONS;

EID: 69749126014     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11310250-000000000-00000     Document Type: Review

References (32)

1. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296 (13): 716-721 (Pubitemid 8066534)
2. Briggs A, Schulpher M, Claxton K. Decision modelling for health economic evaluation. Oxford (UK): Oxford University Press, 2006
3. Willan AR, Briggs AH. The statistical analysis of cost-effectiveness data. Chichester (UK): John Wiley and Sons, 2006
4. Briggs AH. A Bayesian approach to stochastic cost-effectiveness analysis. Int J Technol Assess Health Care 2001; 17: 69-82
5. O'Hagan A, Stevens J. A framework for cost-effectiveness analysis fromclinical trial data. Health Econ 2001; 10: 303-315 (Pubitemid 32605733)
6. O'Hagan A, Stevens J, Montmartin J. Bayesian cost effectiveness analysis from clinical trial data. Stat Med 2001; 20: 733-753 (Pubitemid 32177846)
7. Parmigiani G. Modeling in medical decision making. New York (NY): John Wiley and Sons, 2002
8. Spiegelhalter D, Best N. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling. Stat Med 2003; 22: 3687-3709 (Pubitemid 37483543)
9. Spiegelhalter D, Abrams K, Myles J. Bayesian approaches to clinical trials and health-care evaluation. Chichester (UK): John Wiley and Sons, 2004
10. Russo P. Pharmacoeconomics evaluations in the Italian regulatory context: a qualiquantitative analysis of pricing and reimbursement dossiers. Pharmacoeconomics - Italian Research Articles 2008; 10 (2): 59-75
11. Berger ML, Bingefors K, Hedblom EC, et al. Health care cost, quality, and outcomes: ISPOR book of terms. Lawrenceville (GA): ISPOR, 2003
12. Donaldson C, Currie G, Mitton C. Cost effectiveness analysis in health care: contraindications. BMJ 2002; 325: 891-894 (Pubitemid 35215266)
13. EuroQol. European value of a quality adjusted life year [online]. Available from URL: http://research.ncl.ac.uk/eurovaq [Accessed 2008 Feb]
14. Brouwer W, van Exel J, Baker R, et al. The new myth: the social value of the QALY. Pharmacoeconomics 2008; 26 (1): 1-4
15. Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics 2001; 19: 609-621 (Pubitemid 32531836)
16. Marshall DA, Douglas PR, Drummond MF, et al. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. Pharmacoeconomics 2008; 26 (6): 477-495
17. Mauskopf J, Rutten F, Schonfeld W. Cost-effectiveness league tables: valuable guidance for decision makers? Pharmacoeconomics 2003; 21 (14): 991-1000
18. Taylor RS, DrummondM, Salkeld G, et al. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ 2004; 329: 972-975
19. Detsky AS, Laupacis A. Relevance of cost-effectiveness analysis to clinicians and policy makers. JAMA 2007; 298 (2): 221-224 (Pubitemid 47057770)
20. Stinnett A, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost effectiveness analysis. Med Decis Making 1998; 18 (Suppl.): S68-80 (Pubitemid 28175944)
21. Baio G, Dawid AP. Probabilistic sensitivity analysis in health economics. Research Report 292/08, Department of Statistical Science, University College London, UK, 2008 [online]. Available from URL: http://www.ucl.ac.uk/Stats/ research/Resrprts/psfiles/rr292.pdf [Accessed 2008 Oct]
22. van Hout B, Gordon M, Rutten F. Costs, effects and C/E ratios alongside a clinical trial. Health Econ 1994; 3: 309-319
23. Claxton K, Schulpher M, McCabe C, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 2005; 14: 339-347 (Pubitemid 40514748)
24. Howard R. Information value theory. IEEE Transact System Sci Cybernet 1966; SCC-2 (1) 22-26
25. Felli J, Hazen G. Sensitivity analysis and the expected value of perfect information. MedDecis Making 1998; 18: 95-109 (Pubitemid 28041646)
26. Felli J, Hazen G. A Bayesian approach to sensitivity analysis. Health Econ 1999; 8: 263-268
27. Claxton K. Bayesian approaches to the value of information: implications for the regulation of new pharmaceutical. Health Econ 1999; 8: 269-274 (Pubitemid 29219092)
28. Claxton K, Neumann P, Araki S, et al. Bayesian value-of-information analysis. Int J Technol Assess Health Care 2001; 17: 38-55
29. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence. Lancet 2002; 360: 711-715 (Pubitemid 35232343)
30. Ades A, Lu G, Claxton K. Expected value of sample information calculations in medical decision modeling. Med Decis Making 2004; 24: 207-227 (Pubitemid 38391940)
31. Brennan A, Kharroubi S. Efficient computation of partial expected value of sample information using Bayesian approximation. Research Report 560/05. Sheffield (UK): University of Sheffield, Department of Probability and Statistics, 2005
32. Fenwick E, Palmer S, Claxton K, et al. An iterative Bayesian approach to health technology assessment: application to a policy of preoperative optimization for patients undergoing major elective surgery. Med Decis Making 2006; 26: 480-496 (Pubitemid 44410298)